Beam Therapeutics

📍 Cambridge, United States🗓 Founded 2017👥 575 employees💰 Last funded Sep 2024
Biotechnology Research🌐 beamtx.com
Website LinkedIn
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. Our dream is to provide life-long cures for patients suffering from serious diseases. The Beam Team Is: • A community of fearless innovators • Rigorous and honest in our research • Listening with open minds • Committed to each other
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Liechtenstein
1
Frequently asked questions
Who invested in Beam Therapeutics?
Beam Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Beam Therapeutics last raise funding?
The most recent investment in Beam Therapeutics recorded on gritt.io was in September 2024.
When was Beam Therapeutics founded?
Beam Therapeutics was founded in 2017.
What industry is Beam Therapeutics in?
Beam Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Beam Therapeutics based?
Beam Therapeutics is headquartered in Cambridge, United States.